The stakes are high. Most patients with IgA nephropathy progress to kidney failure within ten to fifteen years of disease onset, making the condition one of the leading causes of end-stage kidney failure globally. The disease is a mesangioproliferative glomerulonephritis characterized by dominant deposition of IgA in the mesangial region of the glomeruli, the filtering units of the kidney. The current multi-hit model holds that patients first accumulate elevated circulating levels of galactose-deficient IgA1, an antibody subtype whose O-linked glycans in the hinge region lack terminal galactose. This aberrant antibody then forms high-molecular-weight immune complexes with IgG and IgA antibodies directed against it, and these complexes deposit in the mesangium, triggering inflammation and progressive scarring. Because production of the galactose-deficient antibody is considered the first and central hit, therapeutic strategies targeting its cellular sources are now under active development.

The pathogenic molecule was identified through elegant analytical chemistry. In 1997, Tomana and colleagues analyzed the O-glycan structures of serum IgA1 by gas chromatography and found IgA1 with galactose-deficient O-glycans in the hinge region, subsequently termed Gd-IgA1. The galactose deficiency exposes N-acetylgalactosamine, which can be detected with the GalNAc-specific lectin Helix aspersa agglutinin. Hiki and colleagues later used mass spectrometry to show that IgA1 deposited in the glomeruli of patients is also characterized by reduced galactosylation and sialylation. The review authors generated the monoclonal antibody KM55, which specifically recognizes the hinge region of human Gd-IgA1, and directly demonstrated that glomerular IgA deposits in IgA nephropathy consist predominantly of the galactose-deficient form. IgA deposition in the mesangium alone, however, is not specific to the disease and can also be observed in lupus nephritis, hepatitis B virus-associated nephropathy, and liver cirrhosis, which is why qualitative abnormalities of the antibody have become such an important research focus.

Evidence points to the mucosal immune system as the predominant site where pathogenic IgA-producing B cells are primed. Glomerular IgA deposits contain J chain, indicating a polymeric form, and secretory component has been detected in a subset of deposits, suggesting mucosal origin. Clinically, many patients experience episodic gross hematuria after upper respiratory or gastrointestinal infections, and interventions targeting mucosal immunity, including tonsillectomy and the targeted-release budesonide formulation Nefecon, improve renal outcomes. A genome-wide association study has identified susceptibility loci related to mucosal immunity, including CARD9 and HORMAD2, which are also associated with inflammatory bowel disease. Within mucosa-associated lymphoid tissue, the tonsils are considered important sites in the nasopharynx-associated compartment, while Peyer’s patches in the terminal ileum are key within the gut-associated compartment. The predominant compartment involved may vary across geographical regions.

Within mucosal lymphoid tissues, B-cell class switch recombination and differentiation into IgA-producing cells are regulated by germinal center-dependent responses and signaling pathways involving toll-like receptors, APRIL, and BAFF. In the germinal center pathway, exogenous antigens taken up by dendritic cells activate naive CD4-positive T cells through MHC class II-dependent presentation, and a subset of these T cells differentiates into follicular helper T cells. Tfh cell-derived CD40 ligand and transforming growth factor-beta play central roles in class switching to IgA, while interleukin-21 and interleukin-10 support the expansion, survival, and differentiation of IgA-switched B cells into antibody-secreting cells. In IgA nephropathy patients, increased frequencies of activated Tfh cells and elevated serum IL-21 levels are associated with higher serum Gd-IgA1 concentrations, and circulating Tfh cell-derived IL-21 correlates with disease activity including the degree of proteinuria. Definitive evidence that germinal center reactions represent the predominant source of pathogenic Gd-IgA1-producing cells is still lacking, but the circumstantial case is strong.

Toll-like receptor signaling provides a second route to aberrant antibody production. TLR9, which recognizes unmethylated CpG DNA from microorganisms, promotes Gd-IgA1 production through induction of interleukin-6 and APRIL and exacerbates glomerular IgA, IgG, and C3 deposition as well as kidney injury in gddY mice, a spontaneous murine model of the disease. TLR9 polymorphisms and aberrant expression have been associated with disease severity and therapeutic responsiveness, and tonsillar TLR9 expression has been linked to the efficacy of steroid therapy combined with tonsillectomy. TLR7, which recognizes microbial single-stranded RNA, similarly aggravates the disease by promoting Gd-IgA1 production, with expression associated with IL-6 production and correlated with APRIL expression in patient tonsils. Consistent with these findings, hydroxychloroquine has produced sustained reductions in proteinuria, and suppression of TLR7/9 signaling has been suggested as one mechanism underlying its therapeutic effects. TLR4, activated by lipopolysaccharide from Gram-negative bacteria, has been proposed to contribute through the TLR4/MyD88/NF-kappaB pathway in response to gut dysbiosis.

APRIL and BAFF, whose expression can be enhanced by toll-like receptor signaling, play pivotal roles in differentiating B cells into IgA-producing cells. Three receptors mediate their signaling: BAFF receptor, which specifically binds BAFF, and the two shared receptors TACI and BCMA. BAFF signaling through BAFFR is critical for the survival of immature and naive B cells, whereas APRIL signaling through TACI and particularly BCMA becomes increasingly important as B cells differentiate into plasmablasts and plasma cells. Consequently, BAFF is thought to predominate in the survival of immature and mature B cells, while APRIL is more closely involved in IgA class switching and the maintenance of antibody-secreting cells. Genome-wide association studies have identified APRIL- and TACI-related loci as susceptibility loci for IgA nephropathy, and recent clinical trials showing that APRIL/BAFF-targeted therapies markedly reduce serum Gd-IgA1 levels and proteinuria further support the role of this pathway in sustaining pathogenic production.

Where the Gd-IgA1-producing cells reside is essential to understanding the chronic course of the disease. Patients exhibit increased numbers of polymeric IgA1-positive plasma cells and IgA1-producing cells in the bone marrow, and experimental studies have shown amelioration of the disease following bone marrow transplantation in murine models, with clinical cases reporting remission after bone marrow or peripheral blood stem cell transplantation for hematologic disorders. Antigen-specific lymphocytes and antigen-presenting cells undergo continuous trafficking between mucosal tissues and bone marrow in humans, leading to the proposal that dysregulation of the mucosa-bone marrow axis promotes mis-homing of Gd-IgA1-producing cells aberrantly primed in mucosal lymphoid tissue to the bone marrow, where they differentiate into long-lived plasma cells that continuously produce the molecule. Recent studies have also identified infiltration of B cells and plasma cells within renal tissues, where intrarenal B cells express TLR7 and produce IL-6, raising the possibility of local Gd-IgA1 production. Circulating Gd-IgA1-expressing B cells in peripheral blood carry preferentially lambda light chains, consistent with mesangial IgA deposits, and express mucosal homing receptors.

Therapeutic strategies now target both the mucosal abnormalities that initiate pathogenic production and specific stages of B-cell differentiation that sustain it. Tonsillectomy alone reduced serum Gd-IgA1 levels and improved hematuria in 59 percent of patients, and steroid therapy combined with tonsillectomy demonstrated higher rates of proteinuria remission, 65.7 versus 35.0 percent, and hematuria remission, 77.1 versus 45.0 percent, compared with steroid therapy alone. Nefecon, a targeted-release formulation of budesonide delivering the drug to the distal ileum, reduced serum Gd-IgA1 by approximately 18 percent and IgA-IgG immune complexes by approximately 7 percent, decreased proteinuria by approximately 27 percent at 9 months, and attenuated the decline in estimated glomerular filtration rate, with sustained renoprotective effects over 2 years and a between-group difference in eGFR of 5.05 mL/min/1.73 m2. However, discontinuation results in re-elevation of serum Gd-IgA1 levels accompanied by recurrence of proteinuria, and long-term efficacy remains to be established. Following accelerated approval by the U.S. FDA in 2021, Nefecon received full approval in December 2023 and has subsequently been approved in Europe and several Asian countries.

The most striking results have come from therapies aimed at later stages of B-cell differentiation. Rituximab effectively depleted peripheral CD20-positive B cells but produced no significant improvements in serum Gd-IgA1 levels, proteinuria, or kidney function after 1 year, suggesting that CD20-negative differentiated plasma cells play a pivotal role. Atacicept, a TACI-Fc fusion protein inhibiting both APRIL and BAFF, reduced serum Gd-IgA1 levels by approximately 60 percent at week 24, sustained through week 72, with an approximately 50 percent reduction in proteinuria and preservation of kidney function. Povetacicept, another dual inhibitor, demonstrated a 77 percent reduction in serum Gd-IgA1 at week 48 with a 64 percent reduction in proteinuria and improvement or resolution of hematuria in approximately 90 percent of patients. Sibeprenlimab, an anti-APRIL monoclonal antibody, reduced serum Gd-IgA1 by approximately 65 percent at 3 months and achieved up to a 62.0 percent reduction in proteinuria at 12 months, while zigakibart produced a 74 percent reduction in serum Gd-IgA1 with a 60 percent reduction in proteinuria at 100 weeks. In contrast, belimumab, an anti-BAFF antibody, has not demonstrated clear clinical efficacy, indicating that APRIL rather than BAFF may play the central pathogenic role. Felzartamab, an anti-CD38 monoclonal antibody aiming to eliminate pathogenic antibody-secreting cells, reduced serum Gd-IgA1 levels and proteinuria by up to 44.8 percent at 9 months with the effect maintained at 24 months, and rilzabrutinib, a Bruton’s tyrosine kinase inhibitor, is currently being evaluated in clinical trials.

Yet the review also confronts an unresolved paradox: not all Gd-IgA1 is pathogenic. Some relatives of patients with familial IgA nephropathy have increased serum Gd-IgA1 levels without developing the disease, and in mice with B cell-specific c1galt1 deletion, markedly elevated serum Gd-IgA1 did not increase glomerular IgA deposition, whereas mucosa-derived IgA1 from patients showed greater mesangial deposition irrespective of its Gd-IgA1 content. An experimental study of anti-APRIL therapy revealed that proteinuria decreased in parallel with improvement in IgA glycosylation during treatment but was maintained even after abnormal glycosylation re-emerged following discontinuation. The CD89-CD71-TGase2 axis has been proposed to promote mesangial deposition, but because the transferrin receptor CD71 is expressed on many cell types, its expression alone cannot explain the selective mesangial deposition. The review authors recently discovered IgA-type anti-mesangial cell autoantibodies, IgA-MESCA, in gddY mice and patients, identifying beta2-spectrin and CBX3 as target autoantigens whose aberrant cell-surface expression appears restricted to mesangial cells. These autoantibodies are detected with high specificity in approximately half of patients, possess the characteristics of Gd-IgA1, and bind to autoantigens presented on the mesangial cell surface, potentially explaining why only a subset of circulating Gd-IgA1 selectively deposits in the mesangium. CBX3-recognizing IgA autoantibodies exhibit cross-reactivity with specific oral bacterial antigens, suggesting induction through molecular mimicry following mucosal infections. Identifying these pathogenic fractions may provide useful biomarkers and facilitate precision therapies, particularly given the challenges in developing standardized assays for anti-Gd-IgA1 autoantibodies due to the heterogeneity of O-glycosylation patterns.

Subject of Research: Immunology

Article Title: Gd-IgA1-targeting therapy in IgA nephropathy ~what is pathogenic Gd-IgA1?~

Article References: Mori, K., Nihei, Y., & Suzuki, Y. (2026). Gd-IgA1-targeting therapy in IgA nephropathy ~what is pathogenic Gd-IgA1?~. Frontiers in Nephrology, 6, Article 1977707. https://doi.org/10.3389/fneph.2026.1977707

Image Credits: AI Generated

DOI: 10.3389/fneph.2026.1977707

Keywords: IgA nephropathy, Gd-IgA1, kidney disease, APRIL, BAFF, B cells, mucosal immunity, Nefecon, autoantibodies, Gd-IgA1-targeting, therapy, nephropathy

The study, published in Frontiers in Lupus, evaluated SK1217 in a pristane-induced lupus mouse model, a widely used experimental system in which a single intraperitoneal injection of the mineral oil tetramethylpentadecane triggers lupus-like symptoms including autoantibody production, immune dysregulation, and renal damage. The researchers, Swetha Kakkerla, Sridhar Kavela, and Sathvika Chintalapani, initially screened four novel antimicrobial and immunomodulatory peptides, SK1203, SK1217, SK1260, and SK1281, for their ability to modulate the lupus-like disease. SK1217, a cationic peptide with the sequence AFWWKAKKFAWAKKFAWWKAW, demonstrated the most promising effects and was selected for detailed dose-response experiments at 1 and 2 mg/kg.

The experimental design was rigorous. Female BALB/c mice, eight weeks old, were randomly divided into six groups of six animals each. One group served as an untreated normal control, while the remaining five received 0.5 mL of pristane intraperitoneally. After an eight-week induction period, peptide treatments began at 2 mg/kg three times per week and continued until the mice reached 30 weeks of age. Serum samples collected at weeks 8, 16, and 30 allowed the team to track disease progression longitudinally, and kidney tissues were examined at the endpoint by light microscopy and Western blotting.

The results on autoantibodies were striking. Vehicle-treated lupus mice showed progressive, time-dependent increases in anti-nuclear antibodies, anti-double-stranded DNA, and anti-nRNP/Sm antibodies, confirming successful disease induction. By week 30, SK1217-treated mice exhibited marked reductions in all of these autoantibodies, as well as in anti-chromatin and anti-single-stranded DNA IgG levels measured by indirect ELISA. Because these autoantibodies form immune complexes that deposit in tissues, activate complement, and recruit inflammatory cells, their suppression represents a direct attack on one of the central mechanisms driving organ damage in lupus.

The peptide also proved to be a potent anti-inflammatory agent. Serum concentrations of the proinflammatory cytokines TNF-α, IL-1β, IL-6, and IL-17, all implicated in lupus pathogenesis and correlated with disease activity, were significantly elevated in vehicle-treated lupus mice but fell substantially after SK1217 treatment, approaching levels seen in non-lupus controls. Mechanistically, Western blot analysis of renal tissue revealed that SK1217 downregulated NF-κB p65 expression and reduced the phosphorylation of JNK and p38 MAPK, two stress-activated kinases central to inflammatory signaling and lupus nephritis progression. This concurrent inhibition of two major intracellular cascades suggests the peptide disrupts the signaling infrastructure that sustains renal inflammation.

Perhaps the most mechanistically revealing findings concerned the humoral immune system. Pristane-induced lupus mice showed elevated serum levels of B-cell activating factor, or BAFF, a cytokine that promotes B cell survival, activation, and plasma cell differentiation. SK1217 treatment at both doses significantly reduced BAFF concentrations. Flow cytometric analysis of splenocytes further showed that the peptide decreased the proportion of CD40-positive activated B cells and CD138-positive plasma cells, accompanied by reduced total serum IgG. This coordinated suppression of BAFF-driven B cell amplification provides a coherent explanation for the observed drop in circulating autoantibodies and positions SK1217 alongside belimumab, the approved anti-BAFF monoclonal antibody, as a therapeutic strategy targeting the same pathway.

Renal protection was equally impressive. Vehicle-treated lupus mice exhibited elevated serum creatinine and blood urea nitrogen, hallmarks of impaired kidney function, along with reduced complement C3 levels consistent with complement consumption by immune complex deposition. SK1217 treatment normalized creatinine and BUN, restored C3 toward control levels, and significantly reduced urinary protein excretion measured over 24-hour metabolic cage collections. Histopathological examination of hematoxylin and eosin-stained kidney sections confirmed reduced glomerular damage in treated animals, providing morphological corroboration of the functional biomarkers.

Notably, the peptide did not act as a blunt immunosuppressant. Flow cytometry of peritoneal lavage cells showed that total peritoneal exudate cell numbers were unchanged between treated and untreated lupus mice, indicating no global depletion of immune cells. Instead, SK1217 selectively reduced the frequency of Ly6C-high inflammatory monocytes, a subset known to drive autoantibody production through type I interferon secretion in a Toll-like receptor 7-dependent manner, while decreasing peritoneal IFN-γ levels. Interestingly, granulocyte numbers increased in the treated group, suggesting a reshaping rather than a wholesale suppression of innate immunity.

The therapeutic landscape for lupus remains constrained. Conventional management relies on glucocorticoids, methotrexate, azathioprine, mycophenolate mofetil, and cyclophosphamide, all of which carry significant long-term toxicity and infection risk, while the heterogeneity and unpredictable course of the disease make uniform treatment responses elusive. Therapeutic peptides offer theoretical advantages including high specificity, low immunogenicity, and modifiable structures, and prior work has shown that cationic host-defence peptides can attenuate lupus-associated immune activation in preclinical models. Challenges such as proteolytic degradation, short half-life, and synthesis cost, however, have historically limited their clinical translation.

The authors conclude that SK1217 exerts multi-target immunomodulatory and renoprotective effects through coordinated suppression of BAFF-driven B cell activation, inflammatory cytokine production, complement activation, and MAPK/NF-κB signaling. They emphasize that further research is needed to fully elucidate the peptide’s mechanisms, evaluate its long-term safety, and explore potential synergies with existing lupus therapies. If those translational steps succeed, SK1217 could represent a genuinely novel class of lupus treatment, one that modulates rather than obliterates the immune system, and one whose journey from a Hyderabad laboratory to the clinic will be watched closely by researchers and patients alike.

Subject of Research: SK1217 peptide efficacy in pristane-induced lupus mice

Article Title: Evaluating the efficacy of SK1217 in attenuating pristane-induced lupus in mice

Article References: Kakkerla, S., Kavela, S., & Chintalapani, S. (2026). Evaluating the efficacy of SK1217 in attenuating pristane-induced lupus in mice. Frontiers in Lupus, 4, Article 1466123. https://doi.org/10.3389/flupu.2026.1466123

Image Credits: AI Generated

DOI: 10.3389/flupu.2026.1466123

Keywords: SK1217, systemic lupus erythematosus, lupus nephritis, pristane model, BAFF, autoantibodies, MAPK/NF-κB signaling, immunomodulatory peptide, renal protection, preclinical study, Evaluating, efficacy

The clinical burden of HMPV is substantial and often underestimated. The virus accounts for approximately 4 to 13 percent of hospitalizations associated with lower respiratory tract infections in children under five, and it is recognized as the second most common viral cause of pediatric lower respiratory disease after respiratory syncytial virus. Globally, HMPV is estimated to produce nearly 502,000 hospitalizations and around 11,300 deaths annually in young children, placing its overall impact somewhere between that of RSV and influenza. Severe disease also strikes older adults and immunocompromised individuals. Part of the difficulty in developing a vaccine lies in the virus’s own biology: HMPV interferes with antiviral signaling pathways, suppresses interferon production, and impairs immune cell function, which helps explain why natural infection produces weak, short-lived protective immunity and why reinfections are common.

To overcome this, the research team cast a deliberately wide net across the viral proteome. They retrieved sequences of all eight major HMPV proteins from the CAN97-83 lineage: the fusion (F) and attachment (G) glycoproteins on the viral surface, the small hydrophobic (SH) protein, the matrix proteins M2-1 and M2-2, the nucleoprotein (N), the phosphoprotein (P), and the large RNA-dependent RNA polymerase (L). Each protein was screened for predicted antigenicity using the VaxiJen v2.0 server. The nucleoprotein scored highest at 0.5286, followed by the phosphoprotein, the polymerase L (0.4770), fusion F (0.4711), attachment G (0.4710), M2-1 (0.4163), SH (0.3781), and M2-2 (0.3630). Including internal and replication proteins alongside the surface glycoproteins reflects evidence that both classes contribute to humoral and cellular immunity, making a multi-antigen approach potentially more protective than designs targeting surface proteins alone.

From these proteins, the team predicted three classes of immune epitopes. Cytotoxic T lymphocyte (CTL) epitopes, which would be presented on MHC class I molecules to CD8-positive killer T cells, were identified with NetCTL v1.2 and the Immune Epitope Database (IEDB) resources. Helper T lymphocyte (HTL) epitopes, presented on MHC class II to CD4-positive helper cells, were predicted with NetMHCIIpan and IEDB tools using 10 to 15 amino acid peptides. Linear B-cell epitopes, the targets of antibody responses, were predicted with the IEDB B-cell prediction tool. Every candidate peptide then passed through a safety and quality filter: VaxiJen confirmed predicted antigenicity above a threshold of 0.4, AllergenFP excluded potential allergens, ToxinPred screened out toxic peptides using a threshold of 0.9, and the IFNepitope server flagged peptides likely to induce interferon-gamma, a cytokine central to antiviral immunity.

The final vaccine constructs each contain 24 non-overlapping epitopes: eight CTL, eight HTL, and eight B-cell epitopes, one of each type drawn from every analyzed HMPV protein. The epitopes were stitched together with peptide linkers chosen for their conventional roles in multi-epitope design: alanine-alanine-tyrosine (AAY) linkers between CTL epitopes to support proteasomal processing, glycine-proline-glycine-proline-glycine (GPGPG) linkers between HTL epitopes, and lysine-lysine (KK) linkers between B-cell epitopes. The core epitope region spans 315 amino acids. What distinguishes this study from earlier HMPV immunoinformatics work is the addition of the human B-cell activating factor (BAFF, a 285-amino-acid TNF family member) or the proliferation-inducing ligand APRIL (250 amino acids) at the N-terminus of each construct, connected through an EAAAK linker. Both molecules naturally regulate B-cell survival, differentiation, and antibody production, and prior experimental vaccine studies have shown that BAFF and APRIL can enhance germinal-center reactions and antigen-specific antibody responses in animal models.

The physicochemical profiles of the two constructs suggest they could, in principle, be manufactured as recombinant proteins. The BAFF-adjuvanted construct comprises 533 amino acids with a molecular weight of 57.8 kilodaltons, while the APRIL-containing version is 496 amino acids and 53.63 kilodaltons. Both are predicted to be stable, with instability indices of 32.98 and 31.76 respectively, values comfortably below the threshold of 40 that flags instability. High aliphatic indices (80.28 and 81.69) and negative grand average hydropathicity scores (-0.455 and -0.425) indicate thermostability and hydrophilicity, the latter suggesting compatibility with aqueous solubility. Both constructs were predicted to be antigenic (VaxiJen scores of 0.6776 for the BAFF version and 0.7243 for the APRIL version) and non-allergenic and non-toxic by the screening tools. Secondary structure predictions from the GOR4 and PSIPRED servers showed a balanced mix of alpha-helices, beta-strands, and random coils, with coils predominating, a pattern the authors interpret as supporting both structural stability and exposed, accessible epitopes.

To probe how the constructs might engage the innate immune system, the team performed protein-protein molecular docking against two Toll-like receptors. TLR4 was chosen because previous experimental studies have implicated it in innate responses to HMPV, while TLR1 was included as an exploratory target, with the caveat that TLR1 normally functions as a heterodimer with TLR2. Using structures generated with AlphaFold and the HADDOCK docking platform, the analysis placed each vaccine construct along the leucine-rich repeat domain of the receptors, with multiple predicted contacts. In the TLR4 complex, hydrogen bonds were predicted between Gln185 and Gln187 of the construct and Asn622 and Ser623 of TLR4, along with electrostatic, hydrophobic, and salt-bridge contacts involving residues such as Glu30, Pro27, and Asp50 on the vaccine side and Arg154, Lys184, and Arg337 on the receptor. The TLR1 complex similarly showed hydrogen bonding between construct residue Gln178 and receptor residues Asn518 and Ser515. The authors are explicit that docking demonstrates only structural compatibility, not binding affinity, receptor activation, or signaling.

An immune simulation with the C-ImmSim server, run over 100 time steps under a defined human HLA background, painted a theoretically favorable response profile. Following a single modeled immunization, IgM antibodies appeared first and peaked around days 10 to 12, followed by a class-switched response dominated by IgG1. Interferon-gamma showed the strongest cytokine response, peaking near day 4, with a prominent early IL-2 peak, a pattern consistent with a Th1-oriented cellular response relevant to antiviral defense. Simulated B-cell populations rose to roughly 470 to 480 cells per cubic millimeter by day 6, memory B cells accumulated progressively, and the helper T-cell compartment expanded to about 5,500 cells before declining, with memory T-helper cells increasing to approximately 400 to 450. Population coverage analysis using the IEDB tool predicted that the selected HLA-restricted T-cell epitopes would cover 100 percent of individuals in all eight geographic populations examined, from Central Africa to East Asia to Europe and the Americas, though the number of epitope-HLA combinations recognized per person varied by region.

The study’s authors and its framing are careful about the limits of the work, and rightly so. Every result, from antigenicity scores to docking poses to simulated cytokine kinetics, is a computational prediction resting on algorithmic assumptions rather than biological measurement. The predicted non-allergenic and non-toxic profiles do not establish clinical safety, and the incorporation of BAFF and APRIL carries its own cautionary note: excessive or dysregulated signaling through this pathway is associated with persistence of autoreactive B cells and autoimmune disease, so these endogenous molecules should not be assumed safer than conventional adjuvants. The BAFF and APRIL receptors that would actually mediate their effects, BAFF-R, TACI, and BCMA, were not docked and remain targets for future study. The authors call for molecular dynamics simulations, binding free-energy calculations, recombinant expression, in vitro immunological assays, and ultimately in vivo studies of immunogenicity, safety, and protective efficacy. Until those experiments are done, the constructs stand as rigorously prioritized candidates, an early but structurally detailed step toward closing a significant gap in respiratory virus prevention.

Subject of Research: Immunoinformatics-guided design of BAFF- and APRIL-adjuvanted multi-epitope vaccine candidates against human metapneumovirus

Article Title: Immunoinformatics-guided design and in silico evaluation of BAFF- and APRIL-adjuvanted multi-epitope vaccine candidates against human metapneumovirus

Article References: Alahmadi, R. M., Awadalla, M., Al-Rawi, H. Z., Mubarak, A., Ali Eltayb, W., Abdalla, M., Yu, H., & Alosaimi, B. (2026). Immunoinformatics-guided design and in silico evaluation of BAFF- and APRIL-adjuvanted multi-epitope vaccine candidates against human metapneumovirus. Frontiers in Virology, 6, Article 1949694. https://doi.org/10.3389/fviro.2026.1949694

Image Credits: AI Generated

DOI: 10.3389/fviro.2026.1949694

Keywords: human metapneumovirus, immunoinformatics, reverse vaccinology, multi-epitope vaccine, BAFF, APRIL, Toll-like receptors, molecular docking, vaccine design, interferon-gamma, HLA population coverage, immune simulation

Neuromyelitis optica spectrum disorder has long been distinguished from multiple sclerosis by its serological signature. In 2004, Lennon and colleagues identified a serum autoantibody that marks the disease and separates it clearly from multiple sclerosis, an antibody directed against aquaporin-4, a water channel protein abundantly expressed on astrocytes at the blood-brain barrier and within the central nervous system parenchyma. The binding of these pathogenic immunoglobulin G antibodies to aquaporin-4 triggers complement activation, inflammatory injury to astrocytes, and secondary damage to neurons and oligodendrocytes. Because the antibody is produced by B lineage cells, the logical therapeutic strategy has been to deplete the cells that generate it.

That strategy has been validated repeatedly. Rituximab, a chimeric monoclonal antibody targeting CD20 on the surface of pre-B cells and mature B cells, entered clinical practice on the strength of open-label series and was later tested in the RIN-1 study, a multicentre, randomised, double-blind, placebo-controlled trial published in The Lancet Neurology in 2020, which established its safety and efficacy in the disorder. Inebilizumab, a humanized anti-CD19 antibody with a broader reach across the B cell lineage because it also targets plasma cell precursors, demonstrated benefit in the N-MOmentum phase 2/3 trial reported in The Lancet in 2019. Complement inhibition with eculizumab, reported in the New England Journal of Medicine in 2019, provided an alternative downstream approach by blocking the terminal complement pathway that the pathogenic antibodies engage.

Now obinutuzumab β, a glycoengineered type II anti-CD20 monoclonal antibody, has produced remarkable results in a phase 3 randomized controlled trial described by Wu and colleagues in Nature Medicine. Unlike type I anti-CD20 antibodies such as rituximab, type II antibodies like obinutuzumab engage CD20 in a manner that promotes direct cell death through non-apoptotic mechanisms and mediates more efficient depletion of certain B cell compartments, including tissue-resident populations that are less accessible to complement-dependent mechanisms. The glycoengineering of the Fc region enhances affinity for activating Fc gamma receptors on effector cells, sharpening antibody-dependent cellular cytotoxicity. These pharmacological distinctions matter, because the depth of depletion achieved within different B cell niches may determine how thoroughly autoantibody production is suppressed.

This is precisely the distinction Nakashima highlights in his analysis. The pathogenic anti-aquaporin-4 antibodies in neuromyelitis optica spectrum disorder are secreted by plasmablasts and plasma cells, differentiated descendants of B cells that express little or no surface CD20 and are therefore invisible to all anti-CD20 therapies. Yet clinical experience shows that depleting CD20-positive B cells nevertheless suppresses disease activity in most patients, implying that the continuously replenished pool of CD20-positive B cells is essential for sustaining the plasmablast population that secretes the pathogenic antibody. Fundamental work by Chihara and colleagues, published in the Proceedings of the National Academy of Sciences in 2011, showed that interleukin-6 signaling promotes anti-aquaporin-4 autoantibody production from plasmablasts, suggesting that the survival and differentiation of antibody-secreting cells depend on signals delivered by the surrounding B cell and immune milieu that anti-CD20 therapy disrupts.

The deeper-versus-broader framing also captures a paradox that clinicians have observed since the earliest rituximab era. Nakashima himself reported, in the Journal of Clinical Neuroscience in 2011, transient increases in anti-aquaporin-4 antibody titers following rituximab treatment, associated with elevated serum levels of BAFF, a B cell activating factor belonging to the tumour necrosis factor family. When B cells are depleted, BAFF levels rise because the cytokine is no longer consumed by its targets, and this surge can paradoxically promote the differentiation of surviving precursors towards antibody-secreting cells. Perumal and colleagues documented disease exacerbation after rituximab induction in a subset of patients, a phenomenon plausibly linked to these humoral dynamics. Any new depleting agent must therefore be evaluated not only for how deeply it depletes circulating B cells but also for how it perturbs the regulatory cytokine networks that govern reconstitution.

Dysregulated B cell differentiation towards antibody-secreting cells is now recognised as a hallmark of the disease, as Hoshino and colleagues described in the Journal of Neuroinflammation in 2022. In patients with neuromyelitis optica spectrum disorder, the balance between naïve B cells, memory compartments, and plasmablasts is shifted, with expanded populations of antibody-secreting cells circulating in the blood and correlating with disease activity. This pathobiology explains why broader depletion strategies, such as those targeting CD19 across a wider span of B cell differentiation including plasmablast precursors, and deeper depletion strategies, such as those using type II anti-CD20 antibodies with enhanced effector function, both hold mechanistic appeal. The phase III results with obinutuzumab β suggest that the depth and character of depletion may translate directly into clinical protection against relapse, the outcome that matters most in a disease where each attack can leave permanent, disabling neurological damage.

The clinical stakes of these distinctions are considerable. Neuromyelitis optica spectrum disorder disproportionately affects women and shows a striking predilection for populations in East Asia, and attacks of optic neuritis and transverse myelitis can cause irreversible blindness and paralysis. Since the identification of the aquaporin-4 antibody, a growing therapeutic armamentarium has emerged, encompassing B cell depletion, complement inhibition, and blockade of the interleukin-6 receptor, each intercepting the autoimmune cascade at a different point. The demonstration that obinutuzumab β achieves striking efficacy adds a potent new option, but it also invites head-to-head comparisons that have not yet been performed, leaving open the question of whether deeper depletion of conventional B cell compartments truly outperforms broader depletion that extends into the plasmablast lineage.

Longer-term considerations also come into focus as depleting therapies mature. Repeated courses of B cell depletion carry implications for humoral immunity, vaccine responses, and infection risk, and the dynamics of B cell reconstitution after obinutuzumab β, with its enhanced potency, may differ meaningfully from those seen after rituximab or inebilizumab. Monitoring strategies based on circulating CD19 and CD27-positive cell counts, serum BAFF levels, and anti-aquaporin-4 antibody titers may ultimately allow clinicians to individualise retreatment intervals, depleting deeply enough to prevent relapse while avoiding the prolonged immunosuppression that extended courses might otherwise impose. Biomarker-driven personalisation of this kind remains aspirational, but the mechanistic groundwork laid over the past two decades makes it increasingly plausible.

What the phase III obinutuzumab β trial ultimately delivers, in Nakashima’s assessment, is both a confirmation and a challenge. The confirmation is that B cell depletion remains the most reliable therapeutic principle yet discovered for aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder, capable of preventing the relapses that define the disease’s destructive course. The challenge is to move beyond the blunt question of whether B cells should be depleted and toward the precise one of which subpopulations sustain the autoimmune process, and how the depth, breadth, and timing of depletion can be tuned to maximize benefit while minimizing risk. As next-generation antibodies push the limits of what depletion can achieve, the field is converging on a richer, more granular understanding of B cell biology in neuroimmunological disease, one in which the architecture of the humoral immune response, rather than its mere suppression, becomes the true target of therapy.

Subject of Research: B cell depletion therapy for aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder

Article Title: Deeper versus broader B cell depletion in neuromyelitis optica spectrum disorder

Article References: Nakashima, I. (2026). Deeper versus broader B cell depletion in neuromyelitis optica spectrum disorder. Nature Reviews Neurology. https://doi.org/10.1038/s41582-026-01269-w

Image Credits: AI Generated

DOI: 10.1038/s41582-026-01269-w

Keywords: neuromyelitis optica spectrum disorder, B cell depletion, obinutuzumab beta, aquaporin-4 antibody, anti-CD20 therapy, plasmablasts, rituximab, inebilizumab, neuroimmunology, phase III trial, BAFF, autoantibody